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ABSTRACT
Background. To evaluate the prognostic meaning of
lymph node micrometastases in breast cancer patients.
Methods. Between January 2000 and January 2003, 1411
patients with a cT1-2N0 invasive breast carcinoma under-
went surgery in 7 hospitals in the Netherlands. Sentinel
lymph node biopsy was done in all patients. Based on
lymph node status, patients were divided into 4 groups: pN0
(n = 922), pN1micro (n = 103), pN1a (n = 285), and pNC1b
(n = 101). Median follow-up was 6.4 years.
Results. At the end of follow-up, 1121 women were still
alive (79.4%), 184 had died (13.0%), and 106 were lost to
follow-up (7.5%). Breast cancer recurred in 244 patients:
distant metastasis(n = 165),locoregionalrelapse (n = 83),
and contralateral breast cancer (n = 44). Following adjust-
ment for possible confounding characteristics and for
adjuvantsystemictreatment,overallsurvival(OS)remained
comparablefor pN0and pN1microandwassigniﬁcantlyworse
for pN1a and pNC1b (hazard ratio [HR] 1.18; 95% conﬁdence
interval [95% CI] 0.58–2.39, HR 2.47; 95% CI 1.69–3.63,
HR 4.36; 95% CI 2.70–7.04, respectively). Disease-free
survival(DFS)wassimilartoointhe pN0and pN1microgroup,
andworsefor pN1aand pNC1b(HR0.96;95%CI0.56–1.67vs
HR 1.64; 95% CI 1.19–2.27, HR 2.95; CI 1.98–4.42). The
distant metastases rate also did not differ signiﬁcantly
between the pN0 and pN1micro group and was worse for pN1a
and pNC1b (HR 1.22; 95% CI 0.60–2.49, HR 2.26; 95% CI
1.49–3.40, HR 3.49; CI 2.12–5.77).
Conclusions. In breast cancer patients survival is not
affected by the presence of micrometastatic lymph node
involvement.
Sentinel lymph node biopsy (SLNB) has replaced axil-
lary lymph node dissection (ALND) for lymph node
staging in breast cancer. Because of the more extensive
pathology examination of sentinel lymph nodes (SLNs),
small metastases are observed more frequently.
1–7 Lymph
node micrometastases (LNMM) or isolated tumor cells are
observed in up to 23% of breast cancer patients.
1,6,7
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DOI 10.1245/s10434-010-1451-zRecent studies have refueled the discussion regarding
the prognostic meaning of LNMM.
8–11 Some authors argue
that LNMM do inﬂuence survival adversely, while others
observed comparable survival for patients with microme-
tastases and patients without metastatic lymph node
involvement. Although the discussion started well before
the introduction of the SLNB, SLNB data are conﬂicting
too. In a previous study we observed similar overall sur-
vival (OS) for patients classiﬁed as pN0 and pN1micro.
12,13
The main weaknesses of that study were a limited follow-
up period and the single-institutional experience.
10
We therefore now report again on the prognostic
meaning of micrometastatic lymph node involvement in a
large cohort of consecutive patients from 7 Dutch hospitals
with long-term follow-up.
PATIENTS AND METHODS
Study Cohort
Data were collected on all patients who underwent sur-
gery including SLNB between January 2000 and January
2003 for cT1–2N0 primary invasive breast cancer in 7 hos-
pitals in the Netherlands: University Medical Center
Utrecht, Diakonessen Hospital Utrecht, St Antonius Hos-
pital Utrecht, Amphia Hospital Breda, Jeroen Bosch
Hospital’s Hertogenbosch, Reinier de Graaf Hospital Delft,
and Canisius Hospital Nijmegen. During the study period
1584 patients underwent surgical treatment. To avoid the
difﬁculty of ascribing patient outcome to tumor-speciﬁc
lymph node status, a number of cases were excluded: pre-
vious history of cancer (n = 84), synchronous contralateral
breast cancer (n = 33), or multifocal carcinoma (n = 56).
The cohort available for analysis consisted of 1411 patients.
SLNB and Pathology Examination of Lymph Nodes and
the Primary Tumor
To visualize and identify SLNs, a preoperative lym-
phoscintigraphy was done, while a patent blue dye
injection (Bleu patente ´ V, Laboratoire Guerbet, Aulnay-
sous-Bois, France) and a c-ray detection probe were used
intraoperatively. The deﬁnitive pathology examination of
SLNs was done according to the Dutch national guidelines:
SLNs were formalin-ﬁxed and parafﬁn-embedded, and
starting from the center at least 3 cuts from both halves
were taken at 250-lm intervals.
14. The sections were
stained both with hematoxylin and eosine (H&E) and
immunohistochemically (IHC) with an antibody against
keratin. When the axillary SLN contained micrometastases
or macrometastases, patients were advised to undergo an
ALND. Lymph nodes retrieved by ALND were examined
by examining 1 central cut from every lymph node.
In addition, the diameter, malignancy grade, and estro-
gen (ER) and progesterone (PR) receptor status of the
primary tumor were assessed. At the time of the study,
HER2/neu status was not routinely examined. There were
institutional differences in the classiﬁcation of malignancy
grade. In 4 hospitals the modiﬁed Bloom and Richardson
(BR) grade was assessed, while the mitotic activity index
(MAI) was preferably used to assess tumor aggressiveness
in the other hospitals.
15 Three hospitals used both methods.
Classiﬁcation of Metastatic Lymph Node Involvement
Lymph node involvement was categorized according to
the 6th edition of the UICC-TNM classiﬁcation: pN0,n o
lymphogenic metastasis; pNitc, isolated tumor cells
(\0.2 mm); pN1micro, regional lymphogenic metastasis with
a size between 0.2 and 2.0 mm; pN1a, 1–3 axillary lympho-
genic macrometastases (at least one [2.0 mm); pN1b,1
positive internal mammary node ([2.0 mm); pN1c, a com-
bination of pN1a and pN1b; pN2, 4–9 ipsilateral axillary
lymphogenic macrometastases; pN3, more than 9 axillary
lymphogenicmacrometastases.
16Originalpathologyreports
were adhered to for the classiﬁcation of metastatic lymph
node involvement. When information regarding the size of
micrometastaseswasmissing,originalslideswerereviewed.
Postsurgical Treatment
According to the Dutch national guideline, adjuvant
systemic and/or radiotherapeutic treatment was based on
axillary lymph node status and primary tumor character-
istics.
14 In patients classiﬁed as pN1micro, the national
guideline did not advise adjuvant systemic therapy on a
routine basis. Acknowledging that the prognostic meaning
of LNMM was unclear, this was routinely discussed with
the patients and the choice to give hormonal therapy and/or
chemotherapy was made by the physician and the patient.
Follow-Up
Follow-up started at the date of ﬁrst operation. Patients
were seen twice yearly during outpatient visits. Follow-up
was concluded between April and November 2008. Dates
of locoregional recurrence, contralateral breast cancer,
bone or visceral metastases, and death were recorded.
Analysis
The main focus of our study was to compare pTNM
pN1micro with pN0. We categorized patients into 4 groups on
the basis of metastases in regional lymph nodes: pN0
(including pNitc, n = 23), pN1micro, pN1a, and pNC1b. The
following outcome measures were deﬁned: overall survival
1658 P. D. Gobardhan et al.(OS), disease-free survival (DFS), and its individual com-
ponents: locoregional recurrence, contralateral breast
cancer, and distant metastases (distinguishing between
bone and visceral). Covariables were hospital, age at
operation, tumor size, BR grade, MAI, ER/PR status,
HER2/neu status, and adjuvant radiotherapy, hormonal
therapy, or chemotherapy.
The relation between lymph node status and patient
outcome was analyzed using Cox proportional hazards
regression. Several models were made for each outcome of
interest: with adjustment for hospital (adjusted model 1),
with additional adjustment for age (continuous), tumor size
(continuous), and BR grade (adjusted model 2), and with
additional adjustment for adjuvant treatment (adjusted
model 3). Other covariables were not included in the
models because of their modest baseline differences (ER
and PR status) and the large number of missing values
(MAI and HER2/neu), as well as to keep the ratio of
variables to the number of outcome events in the models
within reasonable boundaries.
Missing Data and Exploration of Heterogeneity
Not all patients had complete records for all covariables,
mostly due to institutional differences in expressing
malignancy grade and the fact that HER2/neu status was
not assessed routinely before 2004. Missing values inclu-
ded: tumor size (n = 8), BR grade (n = 350), MAI
(n = 505), ER status (n = 41), PR status (n = 55), HER2/
neu status (n = 1215), adjuvant radiotherapy (n = 3),
adjuvant hormonal therapy (n = 12), and adjuvant che-
motherapy (n = 13). Missing values were imputed for all
variables except HER2/neu and MAI, which were conse-
quently not included in multivariable analyses.
As the data were obtained from different hospitals, we
explored heterogeneity in the proportion of patients with
pN1micro and heterogeneity in overall DFS and OS risk
between the hospitals. Also, we assessed heterogeneity
across hospitals in the association between nodal status and
DFS, but not OS as the number of deaths in each hospital
was too small.
A more detailed description of the methods can be found
in the Supplementary Appendix.
RESULTS
The median age of the 1411 patients was 57 years.
Overall, 922 women (65.3%) were classiﬁed as pN0, 103
(7.3%) as pN1micro, 285 (20.2%) as pN1a, and 101 (7.2%) as
pNC1b. Baseline characteristics, in relation to lymph node
status, are shown in Table 1. Notably, women with higher
nodal status were more likely to be younger and had larger
and less well-differentiated primary tumors. No clear
differences were observed for MAI, ER/PR and HER2/neu.
The frequency of patients with pN1micro disease varied
signiﬁcantly between each hospital with a median of 6.3%
(range 4.2%–12.1%) per hospital (P = .006).
At the end of follow-up, with a median of 6.4 years and
totalling 8676 years of observation, 1121 women were still
alive (79.4%), 184 had died (13.0%), and 106 were lost to
follow-up (7.5%). Also, 123 patients died with and 61
patients died without breast cancer recurrence, the overall
death rate was 2.1% per year. Breast cancer recurred in 244
patients: distant metastasis (n = 165), locoregional relapse
(n = 83), and contralateral breast cancer (n = 44). The
annual incidence rates were 1.0% for locoregional recur-
rence, 0.5% for contralateral cancer, and 2.0% for
metastases (visceral: 1.5%; bone: 1.3%). Taking differ-
ences in baseline characteristics into account, overall OS
and DFS were not different between hospitals (P = .49 and
P = .21, respectively).
Adjuvant Postoperative Treatment
Adjuvant hormonal therapy and chemotherapy were
given more frequently with increasing nodal status
(Table 2). In the pN1micro group, 41% received chemo-
therapy and 63% hormonal therapy (20% received both).
Patient Outcome
After adjustment for hospital and differences in age,
tumor size, and BR grade, OS in the pN1micro group was
comparable to OS of patients with pN0 disease (hazard ratio
[HR] 0.99; 95% conﬁdence interval [CI]: 0.49–1.98).
Compared with pN0 disease, OS was gradually worse for
pN1a and pNC1b patients (HR 1.99, 95% CI: 1.41–2.82 and
HR 3.42; 95% CI: 2.21–5.30, respectively; Table 3 and
Fig. 1a). Further adjustment for adjuvant therapy increased
the HR for pN1a and pNC1b, but did not substantially change
the pN1micro risk estimate (Table 3).
Similarly, after adjustment for hospital, age, tumor size,
and BR grade, DFS was not statistically different in the
pN1micro group compared with pN0 patients (HR: 0.84; 95%
CI: 0.49–1.43) and was signiﬁcantly worse for the pN1a or
pNC1b patients (HR: 1.35; 95% CI: 1.02–1.79 and HR:
2.29, 95% CI: 1.60–3.29, respectively; Table 3 and
Fig. 1b). Additional adjustment for adjuvant therapy did
not change the HR between the pN1micro and pN0 groups
and strengthened the HR for both the pN1a and pNC1b
groups compared with pN0 patients (Table 3).
There was a marginal, nonsigniﬁcant, increased risk of
developing distant metastases in the pN1micro group com-
pared with pN0 patients (hospital, age, tumor size, and BR
grade adjusted; HR: 1.10; 95% CI: 0.55–2.22), in contrast
with a substantially increased risk in the pN1a and pNC1b
Micrometastases in Breast Cancer 1659TABLE 1 Baseline characteristics according to lymph node status in 1411 cT1-2 breast cancer patients from 7 Dutch hospitals operated between
2000 and 2003
Characteristic Lymph node status P
pN0 (n = 922) pN1micro (n = 103) pN1a (n = 285) pNC1b (n = 101)
Accrued years of follow-up 5720 642 1733 582
Age (years)
a 58.2 (27.4–89.5) 55.9 (34.9–83.1) 54.0 (32.7–90.7) 51.8 (29.6–84.7) \.001
c
Age (%)
\35 years 2.1% 1.0% 1.1% 4.0%
35–49 years 21.7% 28.2% 33.7% 38.6%
C50 years 76.2% 70.9% 65.3% 57.4% \.001
e
Tumor size (cm)
b 1.7 (0.9) 2.0 (0.9) 2.2 (1.0) 2.7 (1.5) \.001
d
Tumor size (%)
\1 cm 14.6% 3.9% 6.0% 2.0%
1–2 cm 53.6% 52.4% 39.3% 28.7%
2–3 cm 24.0% 33.0% 37.2% 40.6%
C3 cm 7.8% 10.7% 17.5% 28.7% \.001
e
Bloom-Richardson grade (%)
Well differentiated 18.8% 15.5% 13.3% 9.9%
Moderately differentiated 54.8% 69.9% 64.2% 53.5%
Poorly differentiated 26.5% 14.6% 22.5% 36.6% \.001
e
Mitotic activity index
a 6 (0–102) 6 (0–25) 10 (0–72) 10 (0–71) \.001
c
Mitotic activity index (%)
\10 64.1% 70.9% 49.8% 46.5%
C10 35.9% 29.1% 50.2% 53.5% \.001
e
Estrogen receptor positive (%) 79.2% 81.6% 80.4% 78.2% .91
e
Progesterone receptor positive (%) 67.7% 75.7% 76.5% 67.3% .02
e
HER2/neu positive (%) 16.0% 5.9% 18.0% 42.9% .004
e
Records with missing values that were imputed (see supplementary appendix): tumor size: 8 (\1%); Bloom-Richardson grade: 350 (25%);
mitotic activity index: 505 (36%); estrogen receptor status: 41 (3%); progesterone receptor status: 55 (4%). For 1215 records HER2/neu status
was unknown, these values were not imputed (shown here are the results from 196 records)
Percentages may not total 100% due to rounding
a Median (range)
b Mean (standard deviation)
c Kruskall-Wallis test
d One-way ANOVA test
e Chi-square test
TABLE 2 Postsurgical treatment according to lymph node status in 1411 cT1-2 breast cancer patients from 7 Dutch hospitals operated between
2000 and 2003
Therapy Lymph node status P
a
pN0 (n = 922) pN1micro (n = 103) pN1a (n = 285) pNC1b (n = 101)
Radiotherapy (%) 69.2% 63.1% 62.5% 85.1% \.001
Hormonal therapy (%) 18.9% 63.1% 74.0% 72.3% \.001
Chemotherapy (%) 20.1% 40.8% 57.2% 70.3 % \.001
Records with missing values that were imputed (see appendix): adjuvant radiotherapy: 3 (\1%); adjuvant hormonal therapy: 12 (\1%); adjuvant
chemotherapy: 13 (\1%)
a Chi-square test
1660 P. D. Gobardhan et al.groups (hospital, age, tumor size, and BR grade adjusted;
HR: 2.02; 95% CI: 1.39–2.92 and HR: 3.22; 95% CI:
2.06–5.05, respectively; Table 4).
The association between nodal status and DFS (adjusted
for age, tumor size, BR grade, and adjuvant therapy) was
not different between the 7 hospitals (P for interaction
TABLE 3 Lymph node status and overall and disease-free survival for 1411 cT1-2 breast cancer patients (from 7 Dutch hospitals operated
between 2000 and 2003) in a hospital-only adjusted model, after additional adjustment for age, tumor size, and BR grade and after additional
adjustment for adjuvant treatment
No. of
patients
Follow-up
a No.
events
Incidence
rate
b
Adjusted model 1
c Adjusted model 2
d Adjusted model 3
e
Hazard ratio
(95% CI)
P Hazard ratio
(95% CI)
P Hazard ratio
(95% CI)
P
Disease-free survival
All 1411 8182 305 37.28
pN0 922 5418 174 32.12 1.00 (referent) 1.00 (referent) 1.00 (referent)
pN1micro 103 621 16 25.77 0.78 (0.46–1.32) .36 0.84 (0.49–1.43) .52 0.96 (0.56–1.67) .90
pN1a 285 1626 75 46.13 1.47 (1.12–1.92) .006 1.35 (1.02–1.79) .04 1.64 (1.19–2.27) .003
pNC1b 101 518 40 77.22 2.52 (1.78–3.57) \.001 2.29 (1.60–3.29) \.001 2.95 (1.98–4.42) \.001
Overall survival
All 1411 8676 184 21.21
pN0 922 5720 88 15.38 1.00 (referent) 1.00 (referent) 1.00 (referent)
pN1micro 103 642 9 14.02 0.87 (0.44–1.73) .69 0.99 (0.49–1.98) .97 1.18 (0.58–2.39) .65
pN1a 285 1733 57 32.89 2.20 (1.57–3.07) \.001 1.99 (1.41–2.82) \.001 2.47 (1.69–3.63) \.001
pNC1b 101 582 30 51.55 3.43 (2.25–5.22) \.001 3.42 (2.21–5.30) \.001 4.36 (2.70–7.04) \.001
Median follow-up 6.4 years
CI conﬁdence interval
a Follow-up time in years (may not total due to rounding)
b Incidence rate per 1000 women per year
c Adjusted by Cox regression analysis for hospital
d Additionally adjusted by Cox regression analysis for age, age
2, tumor size (for overall survival also tumor size
2), and BR grade
e Additionally adjusted by Cox regression analysis for radiotherapy, hormonal therapy, and chemotherapy
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FIG. 1 a Overall survival for clinically T1-2 breast cancer patients
according to lymph node status. Median follow-up 6.4 years, on the
basis of Cox proportional hazard analyses adjusted for age, age
2,
tumor size, tumor size
2, BR-grade, lymph node status and adjuvant
treatment. b Disease free survival for clinically T1-2 breast cancer
patients according to lymph node status. Median follow-up 6.4 years,
on the basis of Cox proportional hazard analyses adjusted for age,
age
2, tumor size, BR-grade, lymph node status and adjuvant treatment
Micrometastases in Breast Cancer 1661between hospital and nodal status: 0.74). The homogeneity
chi-square P value was .88 for pN1micro HRs between
hospitals, .81 for pN1a, and .75 for pNC1b—all versus pN0—
indicating no evidence of heterogeneity between hospitals.
Sensitivity Analysis with Complete-Case Approach
Analyzing the data with a complete-case approach (thus
without imputation of missing values) yielded similar
results. This approach led on average to marginally stron-
ger relations (on average 1% inﬂation of risk estimates
[standard deviation 18%]).
DISCUSSION
In this multicenter cohort study of breast cancer patients
who underwent SLNB, the presence of LNMM did not
affect outcome. Patients with LNMM did not have signif-
icantly different OS and DFS compared with patients
without lymph node metastases, while they had a sub-
stantially better prognosis than patients with pN1 disease.
The main strengths of the present study are the long
follow-up (close to 6.5 years median) and the multicenter
approach, contributing to a study population more reﬂec-
tive of all breast cancer cases compared with our previous
single institution study.
10 Furthermore, the study cohort is
large with more than 100 patients with LNMM, and we
performed multivariable analyses to control for potential
confounding factors in contrast to the majority of similar
studies until now.
17
A weakness of this study is its retrospective nature.
Pathology procedures were not standardized, leading to
differences between hospitals especially with regard to
classifying malignancy grade. This led to incomplete
information on BR grade and MAI, which was overcome
statistically by imputing data. Furthermore, the observed
frequency of pN1micro patients differed signiﬁcantly
between the hospitals, and the overall 7.3% was lower than
expected. In the aforementioned single-institution study,
we observed LNMM in 11.5% of the patients, and others
have reported frequencies of LNMM in up to 23% of the
patients.
1,6,7,10 Assuming that misclassiﬁcation may have
Table 4 Lymph node status and risk of metastasis for 1411 cT1-2
breast cancer patients (from 7 Dutch hospitals operated between 2000
and 2003) in a hospital-only adjusted model, after additional
adjustment for age, tumor size, and BR grade and after additional
adjustment for adjuvant treatment
No. of
patients
Follow-up
a No.
events
Incidence
rate
b
Adjusted model 1
c Adjusted model 2
d Adjusted model 3
e
Hazard ratio
(95% CI)
P Hazard ratio
(95% CI)
P Hazard ratio
(95% CI)
P
Metastasis, all
All 1411 8413 165 19.61
pN0 922 5604 78 13.92 1.00 (referent) 1.00 (referent) 1.00 (referent)
pN1micro 103 624 10 16.03 1.06 (0.53–2.12) .87 1.10 (0.55–2.22) .79 1.22 (0.60–2.49) .59
pN1a 285 1655 48 29.00 2.13 (1.48–3.05) \.001 2.02 (1.39–2.92) \.001 2.26 (1.49–3.40) \.001
pNC1b 101 530 29 54.72 4.06 (2.63–6.25) \.001 3.22 (2.06–5.05) \.001 3.49 (2.12–5.77) \.001
Metastasis, visceral
All 1411 8524 126 14.78
pN0 922 5664 56 9.89 1.00 (referent) 1.00 (referent) 1.00 (referent)
pN1micro 103 631 8 12.68 1.15 (0.52–2.54) .73 1.21 (0.55–2.69) .64 1.35 (0.60–3.05) .47
pN1a 285 1678 39 23.24 2.39 (1.59–3.61) \.001 2.32 (1.52–3.52) \.001 2.58 (1.62–4.13) \.001
pNC1b 101 552 23 41.67 4.35 (2.66–7.12) \.001 3.50 (2.10–5.83) \.001 3.69 (2.08–6.56) \.001
Metastasis, osseal
All 1411 8479 114 13.44
pN0 922 5635 52 9.23 1.00 (referent) 1.00 (referent) 1.00 (referent)
pN1micro 103 630 6 9.52 1.00 (0.43–2.34) 1.00 0.97 (0.41–2.27) .94 1.01 (0.42–2.41) .99
pN1a 285 1667 37 22.20 2.44 (1.60–3.72) \.001 2.21 (1.43–3.41) \.001 2.34 (1.43–3.84) .001
pNC1b 101 547 19 34.73 3.73 (2.19–6.35) \.001 2.85 (1.64–4.95) \.001 3.10 (1.67–5.73) \.001
a Follow-up time in years (may not total due to rounding)
b Incidence rate per 1000 women per year
c Adjusted by Cox regression analysis for hospital
d Additionally adjusted by Cox regression analysis for age, tumor size, and BR grade
e Additionally adjusted by Cox regression analysis for radiotherapy, hormonal therapy, and chemotherapy
1662 P. D. Gobardhan et al.occurred, the impact of such misclassiﬁcation seems minor,
since outcome endpoints for the different N classes showed
a similar pattern irrespective of the frequency of LNMM in
the hospitals.
Even when adjusting for adjuvant systemic therapy, a
similar outcome was observed in patients with pN0 and
pN1micro disease, and the outcome was substantially better
than the outcome of patients with pN1 disease. As the
estimated risk reductions of adjuvant hormonal and che-
motherapy (0.66 and 0.77, respectively, for OS) were in
line with reported risk reductions of these therapies in
randomized clinical trials, this adjustment is adequate.
18
The controversy regarding the prognostic meaning of
LNMM is not new. Intuitively, it would make sense that
limited lymph node involvement has a limited effect on
prognosis, as the extent of lymph node involvement is
directly related to OS. In older ‘‘ALND’’ studies, when
micrometastases were rarely detected, some reported a
prognostic impact while others did not.
12,13,19 The largest
study, based on population-based SEER-data, showed that
patients with LNMM had a prognosis that was in between
the prognosis of node negative patients and of pN1
patients.
20 The January 2010 7th edition of the American
Joint Committee on Cancer Staging Manual has revised the
staging of LNMM. Traditionally, LNMM was grouped
with macrometastases (stage II and above), but is now
downstaged to stage IB for small tumors, in order to
‘‘indicate the better prognosis for the subset of breast
cancer patients and to facilitate further investigation.’’
21
This revision is based on SEER data, and no reference is
made to other studies.
20 Some studies based on lymph
nodes examined by SLNB suggested a worse DFS in
patients with LNMM without a signiﬁcant effect on OS,
but others, including the previous report from one of the
institutions participating in the present study, did not ﬁnd a
signiﬁcant relation between DFS or OS and the presence of
LNMM.
8,10,11,17
These reports and the present study contrast sharply with
the conclusions from the recently published MIRROR
study that did observe a signiﬁcant impact of both mi-
crometastases and isolated tumor cells on outcome, as well
as a substantial beneﬁcial effect of adjuvant treatment in
these patients.
9 Interestingly, the MIRROR study includes
patients from all Dutch hospitals and was partly conducted
during the same years as the study we currently report on.
Consequently, a substantial proportion of the patients from
the present study were in the MIRROR study too.
The most important difference between the two studies
is the endpoint that was used to draw conclusions. As of
now, the MIRROR study has not reported on OS but
merely on DFS. In our view, the appropriateness of
focusing on DFS is questionable, particularly in patients
with a good prognosis due to a low risk of distant
metastases. In these patients the contribution of contralat-
eral breast cancer and local recurrence to the composite
endpoint DFS is large. In the supplementary appendix
accompanying the published version of the MIRROR study
(accessible through the NEJM website) supplementary
Table 2 lists the 5-year event rates of individual compo-
nents of DFS. While the reported DFS after 5 years was
86% in the pN0 and 76% in the pN1micro group, respectively,
the 5-year rates of distant metastases were 2.8% in the pN0
group and 4.6% in the pN1micro group (without adjuvant
treatment). As such, distant metastases were less frequent
than contralateral breast cancers and locoregional recur-
rences and probably also less common than death due to
unrelated causes, although these data are not presented.
Similarly, the beneﬁcial effects of adjuvant treatment in the
pN1micro group on DFS seem to be largely driven by effects
on contralateral breast cancer and locoregional recurrence.
Based on these observations, we are not convinced that the
reported signiﬁcant DFS difference will translate into an
OS difference. Especially since large breast cancer trials
have reported inconsistent results for DFS and OS.
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The relevance of the prognostic meaning of micromet-
astatic disease in breast cancer patients is the answer to the
clinical problem of whether pN1micro on its own should be
an indication for adjuvant systemic treatment. Indications
for adjuvant systemic therapy based on primary tumor
characteristics have expanded. Hence, nowadays 80% of
the LNMM patients of the present cohort would receive
adjuvant systemic therapy based on the primary tumor
characteristics. The present data from a large multicenter
population with a long-term follow-up do not support the
use of adjuvant systemic treatment in patients only because
they have LNMM. However, this issue warrants ongoing
debate and should be addressed preferably in a randomized
trial using overall survival as its primary endpoint.
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